SpikeWatch
The Champollion Manifesto: Decoding the Language of Spikes
The Hidden Language of Biology
For centuries, the body has spoken in silent signals.
Tau. IL-6. NfL. p-Tau217.
Each one a hieroglyph of decline.
SpikeWatch is here to read them.
The Rosetta Revelation
Just like the Rosetta Stone aligned hieroglyphs, demotic, and Greek—
SpikeWatch aligns molecular spikes, behavioral signals, and AI simulations
to decode the body’s hidden messages before symptoms appear.
Email: guy@neuroteg.com
Pattern is Power
We see what others miss.
We detect the pattern.
From spikes to simulations,
we reveal the body’s pre-symptomatic cries for help.
Breakthrough in SCFA Therapy: A New Frontier for Brain & Metabolic Health
Our research is revealing a potential breakthrough in short-chain fatty acid (SCFA) therapy for brain health, metabolism, and inflammation control. By integrating genomics, microbiome science, and precision dosing strategies, we have uncovered powerful new insights into how SCFAs like Butyrate and Propionate can prevent neurodegenerative diseases and metabolic disorders.
SCFA Therapy for Brain Health & Alzheimer’s Prevention
Early high-dose Butyrate is the most effective strategy to slow cognitive decline, especially in APOE ε4 carriers who are at higher risk for Alzheimer’s.
Gradual SCFA dosing is still beneficial but lacks the early-phase neuroprotection needed to stop disease progression.
Patients with gut dysbiosis show weaker responses to SCFA therapy, highlighting the need for gut microbiome restoration alongside SCFA interventions.
SCFA Therapy for Inflammation & Metabolic Stability
Propionate and Butyrate significantly reduce IL-6 and TNF-α, helping control chronic inflammation in neurodegenerative and metabolic diseases.
Early SCFA intervention prevents metabolic instability, supporting better insulin sensitivity and lipid balance.
APOE ε4 carriers have a harder time stabilizing metabolism, suggesting they need stronger SCFA-based interventions.
OUR STORY
Why This Matters
SCFA therapy could be a game-changer for Alzheimer’s prevention and metabolic health.
A personalized approach—matching SCFA dosing to genetics, microbiome, and cytokines—will maximize therapy effectiveness.
Combining SCFAs with probiotics and gut-health strategies can further enhance results, especially for high-risk individuals.
Email: guy@neuroteg.com
WHY WORK WITH US
3DNasal Digital Twin: Revolutionizing Personalized Neurodegenerative Care
-
Patient Data Integration
- Captures genetic (APOE status), microbiome, immune markers, and cognitive test results from electronic health records (EHRs).
- Utilizes the 3DNasal Olfactory Testing Engine to assess early neurodegenerative risk.
-
🧬 AI-Powered Immune-Neuro Simulations
- Simulates MAIT cell shifts, cytokine dynamics, and microbiome-immune interactions across different therapeutic conditions.
- Predicts immune adaptation, inflammatory rebounds, and personalized drug response.
-
-
Personalized Treatment Optimization
- Adjusts NeuroMAIT-101 dosage, nasal spray formulations, and microbiome interventions based on Digital Twin feedback loops.
- Ensures optimized delivery and patient-specific neuroimmune modulation.
-
Continuous Monitoring & Adaptive Therapy
- Tracks treatment response over time, adjusting therapeutic protocols dynamically.
- Provides doctors with actionable insights to fine-tune interventions for maximum efficacy.
Drive Global Progress Forward.
The 3DNasal Digital Twin is an AI-driven, precision-medicine platform designed to optimize treatments for Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other neurodegenerative conditions. By integrating real-time patient data, multi-omics profiling, and advanced immune-neuro simulations, the Digital Twin provides personalized therapeutic recommendations for NeuroMAIT-101 and other Tribiome-based interventions.
Email: guy@neuroteg.com
Biomarker-Driven Precision Medicine
-
AI-enhanced Digital Twin models immune-cognitive interactions for personalized treatment (Wilkinson et al., 2018).
-
Olfactory dysfunction is an early biomarker of AD, justifying its integration into AI diagnostics (McKhann et al., 2011).
-
Companion diagnostics (CDx) framework could support regulatory approval as an FDA-designated Digital Biomarker.
Regulatory Relevance: NeuroMAIT-101 could be paired with an AI-driven companion diagnostic (CDx) for precision monitoring.